CSL shares are back below $100 after a brutal sell-off. The post Under $100, are CSL shares finally too cheap to ignore? appeared first on The Motley Fool Australia.

Can this giant produce healthy returns or is there more downside to come? The post Here are the latest growth forecasts for ...

Has the market become too pessimistic about Australia's biotech giant? The post CSL shares crash, but is a comeback looming?

We present expert insights, including new ratings and 12-month price targets, after CSL's FY25 report. Investors were rattled by the company's wide-ranging plans to restructure the business, including ...

From blue-chip royalty to bin fire, the company’s staggering fall is a brutal reckoning for the Australian icon lost in its own complacency and hubris.

A healthcare giant has suffered another devastating blow, with shares plunging 20 per cent to a decade low after a new announcement.

The global biotechnology company will brief analysts on its latest downgrade on Monday morning after a horror year for the business.

CSL (ASX: CSL) shares plunged sharply on Monday after the Australian biopharmaceutical giant downgraded its fiscal 2026 ...

Having flagged modest revenue and earnings growth for the full year, CSL now has warned it will go backwards on both metrics.

CSL (ASX:CSL) has outlined a restructuring plan that includes separating its Seqirus influenza vaccine business into a standalone entity. The company is also planning workforce reductions and the ...

SYDNEY--Shares of pharmaceutical company CSL fell early Wednesday as investors react to the sudden departure of chief executive Paul McKenzie and an 80% fall in first-half net profit. The stock was ...